National Register of Actionable Mutations

General Inclusion Criteria for all patients: * Age \>18 years old * Life expectancy 6 months * ECOG performance status 2 * Diagnosis of malignant solid tumor, in advanced stage * Informed consent to data registration and for privacy purposes Additional inclusion criteria for patients that have already carried out a genetic characterisation extended by high throughput methods: ● Availability of the result of the broad spectrum analysis of genetic alterations carried out with high throughput methods on biological samples Additional inclusion criteria for patients that perform the molecular-genetic screening using Foundation Medicine services or in selected italian laboratories: * one of the following criteria: * Patients diagnosed with NSCLC not squamous, not pretreated; * Patients with biliary tract, pancreatic, esophagus, stomach, thymus, CNS, nasopharynx, salivary glands, endometrium and urothelium cancers; * Patients with any disease (including NSCLC) who are progressing disease after treatment with molecular target drugs. For these patients is the availability of a post- treatment biological sample is necessary; * Patients with cancer of unknown primary (CUP); * Young patients (\<40 years) or patients who have exhausted standard lines of therapy, with any advanced/metastatic tumor which, in the opinion of the investigator, may benefit from a genetic-molecular characterization at broad spectrum aimed at a treatment with molecular target therapies. * availability of biological material for testing. * informed consent for testing. Additional exclusion criteria for patients that perform the molecular-genetic screening using Foundation Medicine services or in selected italian laboratories: ● patients who have already received NGS or other high throughput in the same stage of disease.